The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Rapid Growth in the HERG Screening Market

• Current Market Overview: The HERG screening market is experiencing significant growth, with its size increasing from $1.42 billion in 2023 to an expected $1.62 billion in 2024, reflecting a compound annual growth rate (CAGR) of 14.2%.
• Growth Drivers: This rapid expansion can be attributed to increased drug development activities, stricter regulatory requirements, heightened awareness of cardiac safety, and a rising incidence of cardiac disorders.

Forecasted Market Expansion and Emerging Trends

• Future Market Projections: The HERG screening market is projected to grow to $2.60 billion by 2028, with a CAGR of 12.5%.
• Key Factors for Growth: The expansion of personalized medicine, increased outsourcing of drug development activities, growth in emerging markets and research, and a focus on non-cardiac safety assessments are key contributors to this expected growth.
• Major Trends: Advanced in vitro models, integration of genomic and proteomic data, advancements in computational approaches, a focus on pediatric drug safety, and collaborations for data sharing and standardization are anticipated to shape the market.

Read More On The HERG Screening Market Report 2024 – https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Impact of Rising Cardiovascular Disorders on Market Growth

• Prevalence of Heart Disorders: The increase in cardiovascular disorders, driven by unhealthy lifestyles, an aging population, genetic factors, diabetes, and metabolic syndrome, is fueling the demand for HERG screening.
• Cardiac Safety: HERG screening plays a crucial role in identifying potential drug candidates, preventing adverse cardiac events like torsade de pointes (TdP), and improving patient outcomes.
• Statistical Evidence: For example, in the U.S., 1 in 20 adults aged 20 and older have cardiovascular diseases, with 695,000 cases and 375,476 deaths reported in 2021. In the UK, heart attack deaths increased from 19,440 in 2020 to 20,061 in 2021.

Leading Companies and Innovations in HERG Screening

• Key Market Players: Major companies in the HERG screening market include Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, and Charles River Laboratories Inc.
• Innovation in Screening Services: Metrion Biosciences Ltd., for instance, launched a GLP-certified HERG screening service in August 2023. This service enhances cardiac safety in drug development by using the whole-cell patch-clamp technique and adhering to regulatory guidelines like ICH S7A and ICH S7B.

Strategic Collaborations for Enhanced Cardiac Safety

• Collaborative Efforts: In September 2021, ApconiX partnered with PhysioStim to establish a European Center of Excellence for preclinical cardiovascular safety evaluation. This collaboration aims to provide a comprehensive range of preclinical cardiac safety tests, including automated electrophysiology for HERG screening and GLP compliance assays.

Regional Insights and Market Segmentation

• Regional Market Leaders: In 2023, North America was the largest region in the HERG screening market. However, Asia-Pacific is expected to be the fastest-growing region during the forecast period.
• Market Segmentation: The HERG screening market is segmented by type (Gene KCNH2, Mutant KCNH2), ion channel (Voltage-Gated, Ligand Gated), and applications (Antiarrhythmic, Antipsychotic, Antibiotics, and Other Applications).

The HERG screening market is poised for continued expansion, driven by advancements in drug development, increased awareness of cardiac safety, and ongoing innovations in screening technologies. As the prevalence of cardiovascular disorders rises globally, the demand for HERG screening is set to grow, supported by strategic collaborations and the entry of new players in the market.

Request for A Sample Of The Global HERG Screening Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=14392&type=smp